EudraLex directives and variations/extensions MCQs With Answer

EudraLex directives and variations/extensions MCQs With Answer

This quiz collection is designed for M.Pharm students studying Regulatory Aspects of Drugs & Cosmetics (MRA201T). It focuses on EudraLex — the body of European pharmaceutical legislation and guidance — and the regulatory processes for post-authorisation changes, including classifications of variations and extensions. The questions cover the structure of EudraLex, key directives, the classification and practical examples of Type IA/IB/II variations, line extensions, and regulatory procedures under national, mutual recognition and centralised routes. Each item tests conceptual understanding and real-world application so students can confidently handle regulatory submissions, variation classification and decide when an extension or a full application is required.

Q1. What is EudraLex in the context of European pharmaceutical regulation?

• A legal and guidance collection covering EU laws, guidelines and procedures for medicinal products
• A pharmacopoeial monograph compilation for Europe
• An EMA database of clinical trial results only
• A GMP inspection schedule list for European manufacturers

Correct Answer: A legal and guidance collection covering EU laws, guidelines and procedures for medicinal products

Q2. Which volume of EudraLex contains the EU Guidelines for Good Manufacturing Practice (GMP)?

• Volume 1
• Volume 2
• Volume 3
• Volume 4

Correct Answer: Volume 4

Q3. Which Directive is the primary legal framework for medicinal products for human use in the EU?

• Directive 2001/83/EC
• Directive 2010/84/EU
• Directive 2003/94/EC
• Directive 98/79/EC

Correct Answer: Directive 2001/83/EC

Q4. How are post-authorisation changes to a marketing authorisation commonly classified under EU regulatory practice?

• Minor and Major only
• Type I, Type II and Type III
• Type IA, Type IB and Type II
• Administrative and Scientific

Correct Answer: Type IA, Type IB and Type II

Q5. Which variation type generally requires prior regulatory approval before implementation?

• Type IA
• Type IB
• Type II
• Administrative notification only

Correct Answer: Type II

Q6. Which variation type is typically described as a “do-and-tell” change that the marketing authorisation holder can implement immediately and then notify the authority?

• Type II
• Type IB
• Type IA
• Extension application

Correct Answer: Type IA

Q7. A change that affects a critical manufacturing step and could impact product quality and efficacy should be classified as which of the following?

• Type IA minor administrative change
• Type IB minor quality tweak with no review
• Type II major variation requiring prior approval
• No notification required

Correct Answer: Type II major variation requiring prior approval

Q8. The addition of a new pharmaceutical strength to an existing marketing authorisation is best described as:

• An administrative change that never needs data
• A line extension (extension) that often requires substantial supporting data or classification as a major change
• A Type IA change implemented immediately
• A purely packaging change

Correct Answer: A line extension (extension) that often requires substantial supporting data or classification as a major change

Q9. In regulatory terminology, what does an “extension” to a marketing authorisation typically mean?

• Only a change to the manufacturer’s internal quality system
• An expansion of the authorised product scope such as new indication, strength, form or route
• A renewal of the authorisation validity period
• Removal of a minor excipient from the formulation

Correct Answer: An expansion of the authorised product scope such as new indication, strength, form or route

Q10. Which body or document provides the primary guidance on classification of variations in the EU?

• European Commission guidance on classification of variations
• National pharmacopoeia only
• Individual company SOPs without regulatory input
• World Health Organization GMP Annexes

Correct Answer: European Commission guidance on classification of variations

Q11. For centrally authorised products, which agency coordinates the assessment of variation applications?

• The national competent authority of the marketing authorisation holder
• The World Health Organization
• The European Medicines Agency (EMA)
• The European Court of Justice

Correct Answer: The European Medicines Agency (EMA)

Q12. Which statement best describes a Type IB variation?

• It is a major change requiring prior approval and full dossier submission
• It is a minor change that requires notification to authorities and is not considered immediately implementable without following specific rules
• It is an administrative labeling correction only
• It is an extension involving a new indication

Correct Answer: It is a minor change that requires notification to authorities and is not considered immediately implementable without following specific rules

Q13. What is the regulatory difference between a renewal and a variation?

• Renewal updates product chemistry; variation always renews the MA
• Renewal is a periodic confirmation of the authorisation validity; variation is a post-authorisation change to the terms of the authorisation
• There is no difference; both are identical procedures
• Variation only happens at initial approval; renewal only for generics

Correct Answer: Renewal is a periodic confirmation of the authorisation validity; variation is a post-authorisation change to the terms of the authorisation

Q14. Which of the following would typically be classified as a Type IA (minor) change?

• Major change to the therapeutic indication backed by new clinical studies
• Typographical corrections to the SmPC that do not alter meaning
• Change of the manufacturing plant for the active substance affecting a critical step
• Addition of a new strength or dosage form

Correct Answer: Typographical corrections to the SmPC that do not alter meaning

Q15. Which committee within EMA is commonly involved in assessment of major variations for centrally authorised medicines?

• Pharmacovigilance Risk Assessment Committee (PRAC)
• Committee for Herbal Medicinal Products (HMPC)
• Committee for Medicinal Products for Human Use (CHMP)
• Orphan Medicinal Products Committee (COMP)

Correct Answer: Committee for Medicinal Products for Human Use (CHMP)

Q16. What is meant by a “line extension” in EU regulatory practice?

• Minor label wording change
• Introduction of a new formulation, strength, route or indication within the same product family
• Administrative transfer of MAH only
• Change in GMP inspection frequency

Correct Answer: Introduction of a new formulation, strength, route or indication within the same product family

Q17. Under what circumstances might an extension be handled as a new marketing authorisation rather than a variation?

• When the change is only a minor spelling correction
• When the extension significantly alters safety, efficacy or creates a product sufficiently different to require full dossier and independent assessment
• When the MAH prefers faster processing
• When the change is purely administrative and cosmetic

Correct Answer: When the extension significantly alters safety, efficacy or creates a product sufficiently different to require full dossier and independent assessment

Q18. Which types of supporting data are commonly required for a quality-related Type II variation?

• Updated CMC dossier, stability data, validation reports and risk assessment
• Only a one-line statement from the manufacturer
• Marketing materials and sales forecasts
• Clinical study protocols unrelated to the change

Correct Answer: Updated CMC dossier, stability data, validation reports and risk assessment

Q19. What does PASS stand for in the post-authorisation regulatory context?

• Post-Authorisation Safety Study
• Pre-Authorisation Scientific Submission
• Product Approval and Safety Survey
• Pharmacovigilance Administrative Submission Schedule

Correct Answer: Post-Authorisation Safety Study

Q20. Which statement is true regarding implementation of Type II variations?

• They can be implemented immediately and notified later
• They generally require prior approval and must not be implemented until authorised
• They never require any supporting data
• They are only relevant to veterinary products

Correct Answer: They generally require prior approval and must not be implemented until authorised

Download